These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

587 related articles for article (PubMed ID: 21148071)

  • 1. Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2.
    Dangi-Garimella S; Krantz SB; Barron MR; Shields MA; Heiferman MJ; Grippo PJ; Bentrem DJ; Munshi HG
    Cancer Res; 2011 Feb; 71(3):1019-28. PubMed ID: 21148071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatic cancer cells respond to type I collagen by inducing snail expression to promote membrane type 1 matrix metalloproteinase-dependent collagen invasion.
    Shields MA; Dangi-Garimella S; Krantz SB; Bentrem DJ; Munshi HG
    J Biol Chem; 2011 Mar; 286(12):10495-504. PubMed ID: 21288898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Collagen regulation of let-7 in pancreatic cancer involves TGF-β1-mediated membrane type 1-matrix metalloproteinase expression.
    Dangi-Garimella S; Strouch MJ; Grippo PJ; Bentrem DJ; Munshi HG
    Oncogene; 2011 Feb; 30(8):1002-8. PubMed ID: 21057545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
    Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
    Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-dimensional collagen I promotes gemcitabine resistance in vitro in pancreatic cancer cells through HMGA2-dependent histone acetyltransferase expression.
    Dangi-Garimella S; Sahai V; Ebine K; Kumar K; Munshi HG
    PLoS One; 2013; 8(5):e64566. PubMed ID: 23696899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MT1-MMP cooperates with Kras(G12D) to promote pancreatic fibrosis through increased TGF-β signaling.
    Krantz SB; Shields MA; Dangi-Garimella S; Cheon EC; Barron MR; Hwang RF; Rao MS; Grippo PJ; Bentrem DJ; Munshi HG
    Mol Cancer Res; 2011 Oct; 9(10):1294-304. PubMed ID: 21856775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
    Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
    Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
    Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
    Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TRIM11 suppresses ferritinophagy and gemcitabine sensitivity through UBE2N/TAX1BP1 signaling in pancreatic ductal adenocarcinoma.
    Shang M; Weng L; Xu G; Wu S; Liu B; Yin X; Mao A; Zou X; Wang Z
    J Cell Physiol; 2021 Oct; 236(10):6868-6883. PubMed ID: 33629745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysyl oxidase family activity promotes resistance of pancreatic ductal adenocarcinoma to chemotherapy by limiting the intratumoral anticancer drug distribution.
    Le Calvé B; Griveau A; Vindrieux D; Maréchal R; Wiel C; Svrcek M; Gout J; Azzi L; Payen L; Cros J; de la Fouchardière C; Dubus P; Guitton J; Bartholin L; Bachet JB; Bernard D
    Oncotarget; 2016 May; 7(22):32100-12. PubMed ID: 27050073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo.
    Zhi X; Chen W; Xue F; Liang C; Chen BW; Zhou Y; Wen L; Hu L; Shen J; Bai X; Liang T
    Oncotarget; 2015 Sep; 6(28):26230-41. PubMed ID: 26213847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance.
    Chiou SH; Dorsch M; Kusch E; Naranjo S; Kozak MM; Koong AC; Winslow MM; Grüner BM
    Sci Rep; 2018 Sep; 8(1):14008. PubMed ID: 30228296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
    Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE
    J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer.
    Liu C; Shi J; Li Q; Li Z; Lou C; Zhao Q; Zhu Y; Zhan F; Lian J; Wang B; Guan X; Fang L; Li Z; Wang Y; Zhou B; Yao Y; Zhang Y
    Clin Sci (Lond); 2019 Mar; 133(5):645-663. PubMed ID: 30782607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer.
    Liu Y; Li F; Gao F; Xing L; Qin P; Liang X; Zhang J; Qiao X; Lin L; Zhao Q; Du L
    Tumour Biol; 2016 Nov; 37(11):15283-15291. PubMed ID: 27696296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.
    Giovannetti E; Funel N; Peters GJ; Del Chiaro M; Erozenci LA; Vasile E; Leon LG; Pollina LE; Groen A; Falcone A; Danesi R; Campani D; Verheul HM; Boggi U
    Cancer Res; 2010 Jun; 70(11):4528-38. PubMed ID: 20460539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
    Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
    Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
    Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silencing PCBP2 normalizes desmoplastic stroma and improves the antitumor activity of chemotherapy in pancreatic cancer.
    Li Y; Zhao Z; Lin CY; Liu Y; Staveley-OCarroll KF; Li G; Cheng K
    Theranostics; 2021; 11(5):2182-2200. PubMed ID: 33500719
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 30.